{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T08:41:47Z","timestamp":1761986507223},"reference-count":10,"publisher":"American Society of Hematology","issue":"2","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,7,13]]},"DOI":"10.1182\/blood-2017-05-781237","type":"journal-article","created":{"date-parts":[[2017,7,13]],"date-time":"2017-07-13T16:25:35Z","timestamp":1499963135000},"page":"98-100","update-policy":"http:\/\/dx.doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":10,"title":["A molecular roadmap for midostaurin in mastocytosis"],"prefix":"10.1182","volume":"130","author":[{"given":"Jason","family":"Gotlib","sequence":"first","affiliation":[{"name":"STANFORD CANCER INSTITUTE"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"2","key":"2019111906472735600_B1","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1182\/blood-2017-01-764423","article-title":"Response and progression on midostaurin in advanced systemic mastocytosis: KIT D816V and other molecular markers","volume":"130","author":"Jawhar","year":"2017","journal-title":"Blood"},{"issue":"2","key":"2019111906472735600_B2","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1182\/blood-2004-12-4617","article-title":"Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412","volume":"106","author":"Growney","year":"2005","journal-title":"Blood"},{"issue":"6","key":"2019111906472735600_B3","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1038\/leu.2015.24","article-title":"KIT mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on Mastocytosis","volume":"29","author":"Arock","year":"2015","journal-title":"Leukemia"},{"issue":"14","key":"2019111906472735600_B4","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1182\/blood-2013-04-496448","article-title":"Comprehensive mutational profiling in advanced systemic mastocytosis","volume":"122","author":"Schwaab","year":"2013","journal-title":"Blood"},{"issue":"1","key":"2019111906472735600_B5","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/leu.2015.284","article-title":"Additional mutations in SRSF2, ASXL1 and\/or RUNX1 identify a high-risk group of patients with KIT D816V(+) advanced systemic mastocytosis","volume":"30","author":"Jawhar","year":"2016","journal-title":"Leukemia"},{"issue":"9","key":"2019111906472735600_B6","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1038\/leu.2013.119","article-title":"Mutations and prognosis in primary myelofibrosis","volume":"27","author":"Vannucchi","year":"2013","journal-title":"Leukemia"},{"issue":"9","key":"2019111906472735600_B7","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1002\/ajh.24426","article-title":"Next-generation sequencing in systemic mastocytosis: Derivation of a mutation-augmented clinical prognostic model for survival","volume":"91","author":"Pardanani","year":"2016","journal-title":"Am J Hematol"},{"key":"2019111906472735600_B8","first-page":"329","article-title":"Looking forward: novel therapeutic approaches in chronic and advanced phases of myelofibrosis","volume-title":"Hematol Am Soc Hematol Educ Prog","author":"Mascarenhas","year":"2015"},{"issue":"26","key":"2019111906472735600_B9","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1056\/NEJMoa1513098","article-title":"Efficacy and safety of midostaurin in advanced systemic mastocytosis","volume":"374","author":"Gotlib","year":"2016","journal-title":"N Engl J Med"},{"issue":"6","key":"2019111906472735600_B10","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1182\/blood-2015-03-633404","article-title":"Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib","volume":"126","author":"Patel","year":"2015","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/130\/2\/98\/1403742\/blood781237.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/130\/2\/98\/1403742\/blood781237.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T11:47:34Z","timestamp":1574164054000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/130\/2\/98\/36687\/A-molecular-roadmap-for-midostaurin-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,13]]},"references-count":10,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,7,13]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2017-05-781237","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,13]]}}}